JN.1 sub-variant: The Additional Public Health Risk Is Low at the Global Level

JN.1 sub-variant whose earliest documented sample was reported on 25 August 2023 and which was later reported by the researchers to have higher transmissibility and immune escape ability, has now been designated a variant of interest (VOIs) by WHO.

In the last few weeks, JN.1 cases have been reported in many countries. Its prevalence is rapidly increasing globally. In view of rapidly increasing spread, WHO has classified JN.1 as a separate variant of interest (VOI).

As per initial risk evaluation by WHO, the additional public health risk posed by JN.1 sub-variant is low at the global level.

Notwithstanding higher infection rate and possibility of immunity evasion, current evidence does not suggest that the disease severity could be higher compared to other circulating variants.

***

References:

  1. WHO.  Tracking SARS-CoV-2 variants – Currently circulating variants of interest (VOIs) (as of 18 December 2023). Available at https://www.who.int/activities/tracking-SARS-CoV-2-variants
  2. WHO. JN.1 Initial Risk Evaluation 18 December 2023. Available at https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3 

***

Latest

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both...

Future Circular Collider (FCC): CERN Council reviews Feasibility Study

The quest for the answers to the open questions (such as, which...

Chernobyl Fungi as Shield Against Cosmic Rays for Deep-Space Missions 

In 1986, the 4th unit of Chernobyl Nuclear Power Plant in Ukraine...

Myopia Control in Children: Essilor Stellest Eyeglass Lenses Authorised  

Myopia (or near-sightedness) in children is a highly prevalent...

Dark Matter in the Centre of our Home Galaxy 

Fermi telescope made clean observation of excess γ-ray emission...

Newsletter

Don't miss

Planetary Defence: DART Impact Changed both Orbit and Shape of asteroid 

In the last 500 million years, there have been...

First Successful Gene Editing in Lizard Using CRISPR Technology

This first case of genetic manipulation in a lizard...

Adrenaline Nasal Spray for Treatment of Anaphylaxis in Children

The indication for adrenaline nasal spray Neffy has been expanded (by...

Did the SARS CoV-2 Virus Originate in Laboratory?

There is no clarity on the natural origin of...

NISAR: The New Radar in Space for Precision Mapping of Earth  

NISAR (acronym for NASA-ISRO Synthetic Aperture Radar or NASA-ISRO...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced by electric fields. Application of alternating electric fields (TTFields) to solid tumours selectively target and...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both strategic investment and active contribution in shaping its future direction.  Scientific European is an England-based media outlet providing multilingual...

Future Circular Collider (FCC): CERN Council reviews Feasibility Study

The quest for the answers to the open questions (such as, which fundamental particles make dark matter, why matter dominates the universe and why there is matter-antimatter asymmetry, what is force...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.